No CrossRef data available.
Article contents
Narcolepsy, a “sleeping disorder”?
Published online by Cambridge University Press: 18 September 2015
Summary
The narcoleptic syndrome in its most specific way is characterized by a set of clinical symptoms, including cataplexy, irresistable sleep episodes, hypnagogic hallucinations and sleepparalysis; the syndrome has been defined by the association of excessive day-time somnolence and REM-sleep abnormalities. In principle, anamnestic information is sufficient to establish the clinical diagnosis, although neuro-physiological and biochemical data(CSF monoamine metabolites and HLA-typology) are sometimes needed to support the diagnostic procedure. Treatment of excessive daytime somnolence is still primarily based upon CNS stimulants, while treatment of cataplexy and related symptoms rests on antidepressants with a primarily serotonergic mode of action.
Information
- Type
- Research Article
- Information
- Copyright
- Copyright © Scandinavian College of Neuropsychopharmacology 1991
References
Literatuur
2.Yoss, RE, Daly, DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957; 32: 320–8.Google ScholarPubMed
3.Schneider-Helmert, D, Spinweber, CL. Evaluation of L-tryptophan for treatment of insomnia: a review. Psychopharmacol 1986; 89:17.CrossRefGoogle ScholarPubMed
4.Billiard, M. Narcolepsy, clinical features and aetiology. Ann clin Res 1985; 17: 220–6.Google ScholarPubMed
5.Passouant, P, Schwab, RS, Cadilhac, J, Baldy-Moulinier, M. Narcolepsie-cataplexie. Etude du sommeil de nuit et du sommeil de jour. Rev Neurol (Paris) 1964; 3: 415–26.Google Scholar
6.Hishikawa, Y, Tabushi, K, Ueyama, M, Hariguchi, S, Fujiki, A, Kaneko, Z. Electroencephalographic study in narcolepsy: especially concerning the symptoms of cataplexy, sleep paralysis and hypnagogic hallucinations. Proc jap EEG Soc 1963; 52–5.Google Scholar
7.Faull, KF, Guilleminault, Ch, Berger, PA, Barchas, JD. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia. Ann Neurol 1983; 13: 258–63.CrossRefGoogle ScholarPubMed
8.Montplaisir, J, de Champlain, J, Youngh, SN, Missala, K, Sourkes, TL, Walsh, J, Remillard, G. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF. Neurol 1982; 32: 1299–302.CrossRefGoogle Scholar
9.Takahashi, Ss. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault, C, Dement, WC, Passouant, P, eds. Narcolepsy. New York: Spectrum Press 1976: 625–41.Google Scholar
10.Shapiro, WR. Treatment of cataplexy with clomipramine. Arch Neurol 1975; 32: 653–6.CrossRefGoogle ScholarPubMed
11.Godbout, G, Montplaisir, J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol 1986; 9: 46–51.CrossRefGoogle ScholarPubMed
12.Broughton, R, Mamelak, M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J neurol Sci, 1979; 6: 1–6.CrossRefGoogle ScholarPubMed
13.Scrima, L, Hartman, PG, Johnson, FH jr, Hiller, FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiat, 1989; 26: 331–43.CrossRefGoogle ScholarPubMed
14.Broughton, R, Mamelak, M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J neurol Sci 1980; 7: 23–31.Google ScholarPubMed
15.Billard, M, Seignalet, J. Extraordinary association between HLA-DR2 and narcolepsy. Lancet I, 1985; 226–7.CrossRefGoogle Scholar
16.Kramer, DE, Dinner, DS, Braun, WE, Zachary, AA, Teresi, GA. HLA-DR2 and narcolepsy. Arch Neurol, 1987; 44: 853–5.CrossRefGoogle ScholarPubMed
17.Matsuki, K, Honda, Y, Juji, T. Diagnostic criteria for narcolepsy and HLA-DR2 frequencies. Tissue Antigens, 1987; 30: 155–60.CrossRefGoogle ScholarPubMed
- 1
- Cited by